Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma

NPJ Precis Oncol. 2024 Feb 1;8(1):26. doi: 10.1038/s41698-024-00506-z.


Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.